Ozmosi | CN-128 Drug Profile

Product Description

CN128 is designed specifically to be an oral chelation agent for iron-overload conditions and to overcome Deferiprone (a current oral chelator)'s myelo-suppression side effect and low pharmacodynamic efficiency (Sourced from: http://zedepharma.com/importantnotice/index.html)

Mechanisms of Action: Iron Chelator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hangzhou Zed Pharmaceutical Technology Co., Ltd.
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Iron Overload|Thalassemia

Phase 1: Thalassemia|Iron Overload

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
CTR20182220	CTR20182220	P1	Completed	Iron Overload\|Thalassemia	2019-05-06	2025-04-29	Patient Enrollment\|Treatments
NCT03935633	D160605-2	P1	Completed	Thalassemia	2019-05-06	2019-12-22	Primary Completion Date\|Primary Endpoints\|Study Completion Date
CTR20171169	CTR20171169	P1	Completed	Iron Overload\|Thalassemia	2018-10-16	2025-04-29	Patient Enrollment\|Treatments
NCT03673085	D160605	P1	Completed	Thalassemia	2018-10-16	2019-12-22	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date
NCT05355766	A160605-202	P2	Completed	Thalassemia\|Iron Overload	2024-09-23	2025-03-18	Primary Endpoints
NCT04614779	A160605	P2	Completed	Thalassemia\|Iron Overload	2022-08-18	2023-11-27	Primary Endpoints
CTR20201051	CTR20201051	P2	Completed	Iron Overload\|Thalassemia	2022-08-18	2025-04-29
CTR20220915	CTR20220915	P2	Completed	Iron Overload\|Thalassemia	None	2025-08-05	Patient Enrollment\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
11/04/2020	PubMed	Effectiveness of the Iron Chelator CN128 in Mitigating the Formation of Dopamine Oxidation Products Associated with the Progression of Parkinson's Disease.
04/23/2020	PubMed	CN128: A New Orally Active Hydroxypyridinone Iron Chelator.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

CN-128

Alternative Names: cn-128, cn 128, cn128, CN128 Tablets Clinical Status: Inactive Latest Update: 2025-03-14 Latest Update Note: Clinical Trial Update